Compare · GYRE vs NVO
GYRE vs NVO
Side-by-side comparison of Gyre Therapeutics Inc. (GYRE) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GYRE and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 330.3x GYRE ($674.5M).
- GYRE has been more active in the news (10 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 3 for GYRE).
- Company
- Gyre Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $674.5M
- $222.81B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2006
- News (4w)
- 10
- 4
- Recent ratings
- 3
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest GYRE
- Gyre Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure
- Gyre Therapeutics Appoints Three New Members to its Board of Directors
- Amendment: Gyre Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Amendment: SEC Form S-3/A filed by Gyre Therapeutics Inc.
- SEC Form 4 filed by Director Carmichael Gordon
- SEC Form 4 filed by Director Weng Dan
- SEC Form 4 filed by Director Zhang Ping
- SEC Form 4 filed by Director Parry Renate
- SEC Form 4 filed by Director Epstein David M.
- SEC Form 4 filed by Director Nussbaum Rodney L
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S